This illustrates that targeted inhibition of the PI3K/AKT/mTOR cascade not only interrupts the critical signaling continuum linking receptor activation with the metabolic phenotype of RA-FLSs but also establishes a pharmacologically vulnerable locus amenable to precision silencing of pathological activity [73,76] (see Figure 8). The gene discussed is MTOR; the disease is rheumatoid arthritis.